These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12725899)

  • 1. Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
    Carvalho RC; Silva RH; Abílio VC; Barbosa PN; Frussa-Filho R
    Brain Res Bull; 2003 Apr; 60(1-2):115-24. PubMed ID: 12725899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
    Chouinard G
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):36S-44S. PubMed ID: 7537286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
    Bishnoi M; Kumar A; Chopra K; Kulkarni SK
    Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.
    Gao XM; Cooper T; Suckow RF; Tamminga CA
    Neuropsychopharmacology; 2006 Sep; 31(9):1864-8. PubMed ID: 16319911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
    Naidu PS; Singh A; Kulkarni SK
    Neuropharmacology; 2003 Jun; 44(8):1100-6. PubMed ID: 12763102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 11. [Utility of quetiapine in tardive dyskinesia].
    Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
    Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of debilitating tardive dyskinesia with risperidone.
    Rangwani SR; Gupta S; Burke WJ; Potter J
    Ann Clin Psychiatry; 1996 Mar; 8(1):27-9. PubMed ID: 8743646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
    Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS
    Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
    Burger ME; Fachineto R; Alves A; Callegari L; Rocha JB
    Brain Res; 2005 Jan; 1031(2):202-10. PubMed ID: 15649445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
    Jeste DV; Lacro JP; Bailey A; Rockwell E; Harris MJ; Caligiuri MP
    J Am Geriatr Soc; 1999 Jun; 47(6):716-9. PubMed ID: 10366172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of topiramate on oral dyskinesia induced by reserpine.
    Araujo NP; Abílio VC; Silva RH; Pereira RC; Carvalho RC; Gonzalez C; Bellot RG; Castro JP; Fukushiro DF; Rodrigues MS; Chinen CC; Frussa-Filho R
    Brain Res Bull; 2004 Dec; 64(4):331-7. PubMed ID: 15561468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.